Search - tctmd.com

Displaying 81 - 100 of 145

Sort: Relevancy | Date

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

March 12, 2018

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

News Conference News ACC 2018

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

Michael O'Riordan

March 11, 2018

TREAT: No Major Bleeds With Ticagrelor in ACS Patients After Fibrinolysis

News Conference News ACC 2018

TREAT: No Major Bleeds With Ticagrelor in ACS Patients After Fibrinolysis

March 11, 2018

Perioperative MIs Bring Too Many Patients Back to the Hospital After Noncardiac Surgery

News Conference News ACC 2018

Perioperative MIs Bring Too Many Patients Back to the Hospital After Noncardiac Surgery

Yael L. Maxwell

March 10, 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

iFR Cheaper Than FFR Over Trajectory of 1 Year: DEFINE-FLAIR Analysis

News Conference News ACC 2018

iFR Cheaper Than FFR Over Trajectory of 1 Year: DEFINE-FLAIR Analysis

March 10, 2018

Wearable Cardioverter-Defibrillator Fails to Meet Primary Endpoint in First Randomized Trial

News Conference News ACC 2018

Wearable Cardioverter-Defibrillator Fails to Meet Primary Endpoint in First Randomized Trial

March 10, 2018

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

CMR Perfusion Imaging Holds Its Own Against Invasive Approach to Managing Stable Angina

News Conference News ACC 2017

CMR Perfusion Imaging Holds Its Own Against Invasive Approach to Managing Stable Angina

March 22, 2017

Randomised Trial of FFR-guided Complete Revascularization versus Infarct Artery only Treatment in Multivessel STEMI Patients

Presentation ACC 2017

Randomised Trial of FFR-guided Complete Revascularization versus Infarct Artery only Treatment in Multivessel STEMI Patients

Presenter: Pieter Smits

March 20, 2017

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

News Conference News ACC 2017

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

Yael L. Maxwell

March 19, 2017

iFR vs FFR for Guiding Coronary Revascularization – DEFINE-FLAIR

Presentation ACC 2017

iFR vs FFR for Guiding Coronary Revascularization – DEFINE-FLAIR

Presenter: Justin E Davies

March 19, 2017

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

News Conference News ACC 2017

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

March 18, 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

News Conference News ACC 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

March 18, 2017

Live From Washington: ACC 2017, Day Two

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Two

March 18, 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

News Conference News ACC 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Yael L. Maxwell

March 17, 2017

Live From Washington: ACC 2017, Day One

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

March 17, 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

To Stent or Not to Stent? iFR vs FFR Late Breakers at ACC 2017 Seek to Shake Up Treatment Decisions

News Conference News ACC 2017

To Stent or Not to Stent? iFR vs FFR Late Breakers at ACC 2017 Seek to Shake Up Treatment Decisions

March 14, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.